Menopausal hormone therapy is useful in treating women’s vasomotor and urogenital symptoms related to estrogen decline. The Women’s Health Initiative data has guided clinician discussion regarding the risk of developing breast cancer with patients since the late 1990s. Additional studies have evaluated how the type of hormone used, duration of its use, and timing of therapy administration affect a patient’s risk of breast cancer. Acknowledging each of these sub-features can enhance patient care by appropriately selecting patients and mitigating risks in therapeutic planning.
Lambarri W. Weighing Risk against Relief: Menopausal Hormone Therapy and Breast Cancer. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.